AR094761A1 - Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma - Google Patents

Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma

Info

Publication number
AR094761A1
AR094761A1 ARP140100439A ARP140100439A AR094761A1 AR 094761 A1 AR094761 A1 AR 094761A1 AR P140100439 A ARP140100439 A AR P140100439A AR P140100439 A ARP140100439 A AR P140100439A AR 094761 A1 AR094761 A1 AR 094761A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
oral administration
fexofenadine
prepare
composition
Prior art date
Application number
ARP140100439A
Other languages
English (en)
Inventor
Daste Georges
Derouet Benjamin
Renouard Marie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR094761A1 publication Critical patent/AR094761A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica para administración oral, que comprende: 1 - 3,5 %p de pectina de alto contenido en metoxi, 40 - 68 %p de glicerol, 16 - 29 %p de agua, 0 - 1 %p de al menos un tensioactivo, 3 - 5 %p de fexofenadina o una sal de la misma farmacéuticamente aceptable, 12 - 24 %p de un excipiente farmacéutico capaz de complejarse con la fexofenadina o su sal farmacéuticamente aceptable, 0 - 5 %p de al menos otros ingrediente seleccionado del grupo que consiste en: sustitutos del azúcar, agentes saborizantes y/o agentes colorantes, siendo los porcentajes en peso relativos al peso total de la composición, y estando el pH de la composición dentro del intervalo de 2,8 a 3,2. Reivindicación 5: La composición farmacéutica de una cualquiera de las reivindicaciones 1 a 4, en donde el excipiente farmacéutico es b-ciclodextrina. Reivindicación 6: La composición farmacéutica de una cualquiera de las reivindicaciones 1 a 5, que es masticable.
ARP140100439A 2013-02-14 2014-02-12 Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma AR094761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13305173 2013-02-14

Publications (1)

Publication Number Publication Date
AR094761A1 true AR094761A1 (es) 2015-08-26

Family

ID=47739181

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100439A AR094761A1 (es) 2013-02-14 2014-02-12 Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma

Country Status (4)

Country Link
AR (1) AR094761A1 (es)
TW (1) TW201440808A (es)
UY (1) UY35329A (es)
WO (1) WO2014125052A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587106A (zh) * 2018-01-15 2020-08-25 西雅图咖米公司 半固态抗组胺组合物及其制备和使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0812195B1 (en) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物
KR101303479B1 (ko) * 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제

Also Published As

Publication number Publication date
UY35329A (es) 2014-09-30
TW201440808A (zh) 2014-11-01
WO2014125052A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
CU20140068A7 (es) Triazolopiridinas sustituidas
ECSP13013050A (es) Formulación para anticuerpo anti- 4 7
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
AR089004A1 (es) Composiciones farmaceuticas inyectables, metodo, uso
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
BRPI0922804B8 (pt) composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
CY1117118T1 (el) Φαρμακευτικος συνδυασμος για την αγωγη του πονου
CU20120171A7 (es) Triazolopiridinas sustituidas
RS53598B1 (en) TOPICAL PREPARATIONS FOR THE CONSERVATION OR RE-ESTABLISHMENT OF MALFIN INTEGRITY
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112013028776A2 (pt) kit, e, uso de uma composição farmacêutica ou nutracêutica
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
UY35848A (es) Tienopirimidinas
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
DOP2016000007A (es) Pirazolpiridinas sustituidas
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure